Frequencies of CV-AEs and AT-AEs across the 5 frontline TKI modalities
| . | IM400, n = 71 . | IM800, n = 203 . | Nilotinib, n = 108 . | Dasatinib, n = 106 . | Ponatinib, n = 43 . | P* . | Overall, N = 531 . |
|---|---|---|---|---|---|---|---|
| Median follow-up (range), mo | 146 (2-196) | 136 (2-186) | 77 (3-134) | 85 (8-132) | 42 (5-55) | .001 | 94 (2-196) |
| Peak systolic BP, median (range), mm Hg | 148 (110-189) | 145 (97-211) | 144 (103-223) | 146 (106-184) | 146 (102-215) | .88 | 146 (97-223) |
| Peak diastolic BP, median (range), mm Hg | 79 (56-96) | 80 (52-139) | 80 (65-135) | 80 (60-97) | 82 (60-112) | .54 | 80 (52-139) |
| CV-AE,*n (%) | 35 (49) | 90 (44) | 44 (41) | 41 (39) | 27 (63) | .13 | 237 (45) |
| Hypertension | |||||||
| Overall | 34 (48) | 76 (37) | 26 (24) | 16 (15) | 23 (53) | <.001 | 175 (33) |
| New | 22 (31) | 35 (17) | 11 (10) | 1 (1) | 9 (21) | .24 | 78 (15) |
| Worsening | 12 (17) | 41 (20) | 15 (14) | 15 (14) | 14 (33) | .05 | 97 (18) |
| Arrhythmia | 3 (4) | 16 (8) | 16 (15) | 21 (20) | 1 (2) | .001 | 57 (11) |
| Palpitations | 0 (0) | 5 (2) | 4 (4) | 8 (7) | 1 (2) | .08 | 18 (3) |
| Prolonged QT interval | 1 (1) | 1 (1) | 3 (3) | 3 (2) | 1 (2) | .35 | 8 (1) |
| Pericarditis | 1 (1) | 2 (1) | 2 (2) | 1 (1) | 1 (2) | .80 | 7 (1) |
| PVD | 0 (0) | 2 (1) | 1 (1) | 1 (1) | 0 (0) | .99 | 4 (1) |
| AT-AE,*n (%) | 5 (7) | 9 (4) | 11 (10) | 15 (14) | 6 (14) | .03 | 46 (9) |
| CAD | 3 (4) | 5 (3) | 7 (6) | 9 (8) | 2 (5) | .15 | 26 (5) |
| CVA (stroke/TIA) | 1 (1) | 2 (1) | 3 (3) | 3 (3) | 2 (5) | .13 | 11 (2) |
| PAD | 0 (0) | 2 (1) | 0 (0) | 2 (2) | 2 (5) | .11 | 6 (1) |
| Pulmonary hypertension | 0 (0) | 0 (0) | 1 (1) | 7 (7) | 1 (3) | <.001 | 9 (2) |
| CHF | 0 (0) | 6 (3) | 2 (2) | 4 (4) | 0 (0) | .47 | 12 (2) |
| Carotid artery occlusion | 0 (0) | 0 (0) | 0 (0) | 3 (3) | 1 (1) | .03 | 3 (1) |
| . | IM400, n = 71 . | IM800, n = 203 . | Nilotinib, n = 108 . | Dasatinib, n = 106 . | Ponatinib, n = 43 . | P* . | Overall, N = 531 . |
|---|---|---|---|---|---|---|---|
| Median follow-up (range), mo | 146 (2-196) | 136 (2-186) | 77 (3-134) | 85 (8-132) | 42 (5-55) | .001 | 94 (2-196) |
| Peak systolic BP, median (range), mm Hg | 148 (110-189) | 145 (97-211) | 144 (103-223) | 146 (106-184) | 146 (102-215) | .88 | 146 (97-223) |
| Peak diastolic BP, median (range), mm Hg | 79 (56-96) | 80 (52-139) | 80 (65-135) | 80 (60-97) | 82 (60-112) | .54 | 80 (52-139) |
| CV-AE,*n (%) | 35 (49) | 90 (44) | 44 (41) | 41 (39) | 27 (63) | .13 | 237 (45) |
| Hypertension | |||||||
| Overall | 34 (48) | 76 (37) | 26 (24) | 16 (15) | 23 (53) | <.001 | 175 (33) |
| New | 22 (31) | 35 (17) | 11 (10) | 1 (1) | 9 (21) | .24 | 78 (15) |
| Worsening | 12 (17) | 41 (20) | 15 (14) | 15 (14) | 14 (33) | .05 | 97 (18) |
| Arrhythmia | 3 (4) | 16 (8) | 16 (15) | 21 (20) | 1 (2) | .001 | 57 (11) |
| Palpitations | 0 (0) | 5 (2) | 4 (4) | 8 (7) | 1 (2) | .08 | 18 (3) |
| Prolonged QT interval | 1 (1) | 1 (1) | 3 (3) | 3 (2) | 1 (2) | .35 | 8 (1) |
| Pericarditis | 1 (1) | 2 (1) | 2 (2) | 1 (1) | 1 (2) | .80 | 7 (1) |
| PVD | 0 (0) | 2 (1) | 1 (1) | 1 (1) | 0 (0) | .99 | 4 (1) |
| AT-AE,*n (%) | 5 (7) | 9 (4) | 11 (10) | 15 (14) | 6 (14) | .03 | 46 (9) |
| CAD | 3 (4) | 5 (3) | 7 (6) | 9 (8) | 2 (5) | .15 | 26 (5) |
| CVA (stroke/TIA) | 1 (1) | 2 (1) | 3 (3) | 3 (3) | 2 (5) | .13 | 11 (2) |
| PAD | 0 (0) | 2 (1) | 0 (0) | 2 (2) | 2 (5) | .11 | 6 (1) |
| Pulmonary hypertension | 0 (0) | 0 (0) | 1 (1) | 7 (7) | 1 (3) | <.001 | 9 (2) |
| CHF | 0 (0) | 6 (3) | 2 (2) | 4 (4) | 0 (0) | .47 | 12 (2) |
| Carotid artery occlusion | 0 (0) | 0 (0) | 0 (0) | 3 (3) | 1 (1) | .03 | 3 (1) |
New-onset hypertension after starting TKI without any prior history of hypertension; worsening is hypertension after TKI in patients with a prior history of hypertension.
BP, blood pressure; TIA, transient ischemic event.
Bold indicates significant P values (P < .05).